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Significance of Patient Registries for
Dermatological Disorders
Mark P. de Souza1 and Vanessa Rangel Miller2
Patient registries for dermatological disorders are important sources of data for
researchers, clinicians, and patients. The majority of registries are maintained by
academic investigators with funding from federal agencies. However, these registries
are fragmented and are maintained only as long as federal funding exists. Patient
organizations and companies can serve as alternative sources of funding for registries.
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Patient registries are databases containing
personal, medical, social, and financial
data reported by a healthcare professional
or by a patient or caregiver. For rare
disorders, registries provide important epi-
demiological data to researchers (e.g.,
incidence and prevalence, symptoms,
and severity to characterize the disorder),
healthcare professionals (e.g., standard of
care, diagnosis and prognosis), and regis-
try participants (e.g., research projects,
clinical trials with potential treatments).
Registries can support policy initiatives
and advocacy, and they provide data that
often lead to deeper engagement among
patients, families, researchers, doctors,
and others in the healthcare community.
Objectives of patient registries
There are several objectives of patient
registries:
(1) Characterize and describe the experi-
ences of affected individuals.
(2) Identify patients and treating physi-
cians.
(3) Assist the development of clinical
care guidelines and improvements
in care quality and disease outcomes.
(4) Facilitate basic, translational, and
clinical trials, including those testing
new therapies.
(5) Encourage research, including geno-
type–phenotype correlations, and
publication.
(6) Collect and store DNA and other
biological/tissue samples from affec-
ted and unaffected family members.
(7) Collect post-marketing surveillance
data for approved drugs.
Registries can capture data reported
by healthcare professionals or by
patients or their caregivers. The data
may be collected in an anonymous
manner or in an identified manner with
necessary informed consent, data pro-
tection, and security measures compli-
ant with current privacy and security
regulations, e.g., the Health Insurance
Portability and Accountability Act of
1996. De-identified data may be avail-
able to qualified researchers who ana-
lyze data from the registry in preparation
of a research publication or clinical
study. The capture of and access to data
for analysis has greatly improved with
the shift in data collection, storage, and
controlled retrieval from cumbersome,
paper-based registries to efficient web-
based electronic databases.
Quality control, updates, and
accessibility are critical
Quality control of the registry data is
paramount, and many registries have
dedicated nurses, curators, genetic coun-
selors, or researchers who assist the
principal investigator to ensure that data
are complete and accurate. Although data
collected by a healthcare professional
tend to be more accurate than patient-
or caregiver-reported data (Kehoe et al.,
1994), both types of data collection are
important, especially for rare diseases, as
there is often a paucity of information in
the literature. Patients or caregivers with a
rare disease are frequently highly motiva-
ted to contribute data to a registry and can
provide first-hand information, e.g., the
personal, social, and financial costs of a
rare disease, that is not easily accessed by
healthcare professionals or not generally
reported in the literature (Rangel et al.,
2012). Registry curators review collected
data and resolve inconsistent responses,
a vital step in ensuring the accuracy of the
data collected in patient-entered registries.
Recruitment of patients for clinical
trials can often take a long period of
time, especially for rare disorders. This
can slow down the development of new
therapies and increase development
costs. An up-to-date registry can accel-
erate the process (Nurok et al., 2010) and
reduce the time and costs of reaching full
recruitment, by targeted communication
with prescreened patient participants
and providing data to expedite study
planning and feasibility assessments.
To maintain the utility of registries as a
tool to facilitate research over time, it is
important that participants’ profiles be
regularly updated.
In the past, maintaining an up-to-date
registry was a major responsibility of
the Registry Coordinator or the Principal
Investigator, accomplished during patient
visits or via telephone. With web-based
registries, the logistics of updating the
registry are greatly facilitated. For exam-
ple, automated emails can be sent by the
online registry via the Registry Coordina-
tor on a periodic (e.g., annual, quarterly,
or other) basis to prompt participants to
provide missing information and update
critical data points. A regular update of
participant profiles can often provide
researchers with valuable longitudinal
data, establish baselines and natural his-
tory for rare disorders, and facilitate cost-
effectiveness comparisons of therapies
once they are available.
Accessibility of data in a patient
registry is critical to generating a better
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understanding of a rare disorder. Unfortu-
nately, many registries established by
academic investigators are not readily
accessible to patients or investigators out-
side the sponsoring investigator’s facility,
hospital, or university. Multiple registries
for a single disease may emerge, and
because no data collection standards exist
investigators collect different data points
using different methods and coding sys-
tems, squandering the potential value of
a single well-controlled registry. Further-
more, owing to the expense of translation,
registries are often available in only one
language. For these reasons, the data
collected for rare diseases tend to be frag-
mented, limiting pan-disorder analysis.
Organizations such as Orphanet, NORD,
and EURODIS, as well as the Office of
Rare Diseases Research (ORDR, National
Institutes of Health), are attempting to
unify the existing, disparate registries for
rare disorders, and, where none exist, to
set up a single, broadly accessible registry
for specific disorders. In addition, an
information model and data standards
have been proposed by the ORDR to
aggregate patient registry data and support
research across rare diseases (Office of
Rare Diseases Research, 2012).
Greater cooperation among
stakeholders needed to consolidate
registries
Different stakeholders create and main-
tain patient registries for different rea-
sons. In one survey of Orphanet, 95.3%
of registries in Europe were sponsored
by or hosted by academic institutions,
3.1% by companies, and 1.6% by
patient organizations (n¼514 registries)
(Orphanet, 2011). Although academic
investigators may establish a registry for
epidemiological research or clinical trial
purposes, drug companies may set up
a registry to comply with post-marketing
surveillance requirements agreed upon
with regulatory authorities. Patient or
disease foundations may set up regis-
tries for advocacy, educational, or fund-
raising purposes.
Some countries, especially the Scan-
dinavian countries, established national
hospital registries several decades ago,
and these registries are organized in
a structured manner to provide access
to administrative and clinical data. The
Danish National Patient Register is prob-
ably the most comprehensive of these
national registries (Lynge et al., 2011).
Thus, for a single disease, there can be
multiple registries organized by different
academic institutions, patient organiza-
tions, federal agencies, or companies.
For example, there are currently 29
patient registries for Duchenne Muscular
Dystrophy in Europe listed on Orphanet,
an online rare disease and orphan
drug database (accessed April 4, 2012).
Would it not be easier for patients, their
caregivers, healthcare professionals, and
researchers to have one centralized regis-
try for DMD? Rare dermatologic diseases
are not immune to registry proliferation
because of their limited patient popula-
tions. Patient organizations, academic
institutions, researchers, and companies
could work together to set up a unified
patient registry for each rare disorder.
Patient organizations, rare disease
advocacy groups, and companies can
provide funding for registries
There are a number of registries for
dermatological disorders (Table 1). In
the United States, the NIH has provi-
ded the funding for several patient regis-
tries in dermatology, including those for
ichthyosis (1994–2004), alopecia areata
(2000–2012), epidermolysis bullosa
(1986–2002), and scleroderma (2001-
current). Such government support was
critical to providing much-needed epi-
demiological data for these disorders,
especially for rare disease subtypes,
and there have been several publications
resulting from these registries. Unfor-
tunately, it has been challenging for
principal investigators, universities, and
Epidermolysis Bullosa (EB) Registries: A Case
Study
The US National EB Registry (NEBR) provided a wealth of clinical, laboratory,
and epidemiological data on patients with all forms of EB (Fine et al., 1999). This
registry was funded by the National Institutes of Health (NIH) from 1986 to 2002.
Unfortunately, this paper-based registry ceased operations despite the best
efforts of the investigators and the Dystrophic Epidermolysis Bullosa Research
Association (DEBRA) of America, the EB patient association, to obtain funding to
continue the pioneering research enabled by the NEBR.
As the NEBR ceased operations, individual EB centers in the United States have
maintained their own EB patient registries, as do EB centers in the European
Union, Japan, Chile, and Mexico. A group of European investigators recently
launched a registry that collects phenotypic and genotypic information on
dystrophic EB (DEB) patients described in the literature and unpublished data
from investigators who have characterized DEB patients (van den Akker et al.,
2011). Genotypic and phenotypic data from DEB patients in other registries, e.g.,
the Australasian EB registry (Kho et al., 2010), are being added to the European
registry.
A US Clinical Research Consortium comprising ten EB centers in the United
States recently launched a physician-reported registry for the clinical character-
ization of EB patients in the United States (http://dermatology.stanford.edu/gsdc/
eb_clinic/trials/eb-ebcrc.html).
On 29 February 2012, DEBRA of America and DEBRA International launched
EBCare (http://www.ebcare.org), an online registry with patient-reported data that
will provide researchers with additional insights into EB symptoms from a
patient’s perspective while providing data on the financial, physical, emotional,
and social burden of illness on patients and their families.
Information from the EB registries will help guide the design of new clinical
studies, provide data on the quality of life of patients with EB, and help better
quantify the burden of illness and the costs associated with EB treatment, which
could help rationalize reimbursement of novel therapies for EB in today’s budget-
constrained environment.
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patient organizations to sustain funding
for these registries.
When NIH funding for the Alopecia
Areata Research Registry ended on
March 31, 2012, the National Alopecia
Areata Foundation continued to fund
the registry. However, likely because
of limited funding, no additional sam-
ples are being taken for the biobank,
although the data in the registry are still
being maintained.
Patient foundations do not always
have adequate funding to set up and
support registries. In the editorial in this
issue, Dr. Fleckman (2012) informs us
that the National Registry of Ichthyosis
and Related Disorders is ceasing opera-
tions owing to the withdrawal of support
from its financial sponsor, the Founda-
tion for Ichthyosis and Related Skin
Types, a patient organization.
Other patient organizations have
done a remarkable job of setting up
and funding patient registries. We
believe that the example set by the
Cystic Fibrosis Foundation (CFF) should
be aspirational for other rare disease
foundations seeking to establish patient
registries. In their 2010 patient registry
report, the CFF claims 26,263 US parti-
cipants, a remarkable 88% of the esti-
mated 30,000 patients in the United
States. The success of the cystic fibrosis
(CF) patient registry is attributable to
the considerable funding provided by
the CFF, which is well capitalized,
with $313 million in 2010 revenues,
consisting of $118 million received in
donations from the public, and the
remainder from investments, pharmacy
services, and royalties (Cystic Fibrosis
Foundation, 2011).
In addition to capturing data from most
patients in the United States, the CF regis-
try also meets Food and Drug Admin-
istration (FDA) requirements, which
enables the CFF (along with pharma-
ceutical industry drug manufacturers) to
monitor the long-term safety of FDA-
approved therapeutics. In addition, the
US CF registry model is being adopted
outside the United States. The CF
foundations in the UK and New Zealand
launched their CF registries in 2011.
Companies developing orphan drugs
for rare dermatological disorders can
benefit from the active participation of
patients and disease advocacy organiza-
tions. Partnership among these stake-
holders provides the opportunity to
establish a trusted network and a founda-
tion for research and registry activities.
Companies developing and commercia-
lizing orphan drugs offer a potential
source of long-term funding of interna-
tional patient registries. These registries
may be set up and maintained in colla-
boration with patient organizations or
disease foundations. For example, in the
past 18 months, two international patient
registries for rare dermatological disorders
were launched by patient foundations
with corporate funding:
(1) The National Foundation for Ecto-
dermal Dysplasias (NFED) launched
the Ectodermal Dysplasias Inter-
national Registry with funding from
Table 1 Selected patient registries in dermatological disorders
Disorder Sponsor Registry web site
Alopecia areata National Alopecia Areata Foundation http://www.mdanderson.org/education-and-research/departments-programs-
and-labs/programs-centers-institutes/alopecia-areata-registry/index.html
Atopic dermatitis National Institute of Allergy and
Infectious Diseases
http://clinicaltrials.gov/ct2/show/NCT01494142
Cutaneous lupus University of Texas Southwestern http://www.utsouthwestern.edu/education/medical-school/departments/
dermatology/research/cutaneous-lupus-registry
Ectodermal dysplasia National Foundation for Ectodermal
Dsyplasias, with funding from Edimer
Pharmaceuticals
https://nfed.patientcrossroads.org/
Epidermolysis bullosa Dystrophic Epidermolysis Bullosa Research
Association funded by Lotus Tissue Repair
www.ebcare.org (patient-reported data)
COL7 mutation database http://www.deb-central.org/molgenis.do (physician-reported database of
COL7A mutations)
Hereditary angioedema Herediatry Angioedema Association, with
funding from Dyax, CSL Behring, Shire,
Viropharma
http://www.haea.org/get-involved/us-haea-scientific-registry
Icthyosis Foundation for Ichthyosis and Related
Skin Types
http://depts.washington.edu/ichreg/ichthyosis.registry/
Pachyonychia congenita Pachyonychia Congenita Project http://www.pachyonychia.org/
Pediatric eczema Valeant Pharmaceuticals https://enroll.thepeerprogram.org/followup/FollowupLogin.action
Psoriasis Medical University, Graz http://www.psoriasis-therapieregister.at
Scleroderma family registry
and DNA repository at
University of Texas
University of Texas, NIH http://www.uth.tmc.edu/scleroderma_reg
Xeroderma pigmentosum Xeroderma Pigmentosum Family Support
Group
http://xppatientregistery.net/
Abbreviation: NIH, National Institutes of Health. The table does not include a number of registries for skin cancers.
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Edimer Pharmaceuticals, a com-
pany developing EDI200, a protein
therapy, to treat the symptoms of
patients affected by X-linked hypo-
hidrotic ectodermal dysplasia (https://
nfed.patientcrossroads.org/).
(2) The Dystrophic Epidermolysis Bul-
losa Research Association (DEBRA)
launched EBCare, the first online
international patient-reported registry
for all forms of epidermolysis bullosa
(http://www.ebcare.org), with funding
from Lotus Tissue Repair, a company
developing recombinant collagen VII
for treatment of dystrophic epidermo-
lysis bullosa.
Multiple companies may jointly spon-
sor a shared registry for a specific dis-
ease, thereby sharing costs and reducing
both patient fragmentation and patient
survey fatigue, within a framework that
protects intellectual property.
Unlike academic registries that are
usually presented only in one language
and in a few countries, company-spon-
sored registries are usually international
registries that are translated into several
major languages. For example, the
NFED registry is currently available in
English, Spanish, German, French, and
Italian. Thus, well-funded, company-
sponsored, multilingual registries can
facilitate collection of data in a single
unified database.
To address the unmet needs shared
throughout the rare disease community,
the NIH ORDR has recently launched the
Global Rare Diseases Patient Registry and
Data Repository (http://grdr.info) program
(Rubinstein et al., 2010). Through a pilot
program, new registries will be deve-
loped using the PatientCrossroads web-
based patient registry program (http://
www.patientcrossroads.com), and an
infrastructure will be developed to create
a repository of patient natural history
and biorepository information. The GRDR
repository will enable analyses of data
across rare diseases and will facilitate
clinical trials and research studies, thereby
accelerating rare disease research.
Although there is no single solution to
securing sustained funding for patient
registries, it is disappointing that registries
that were maintained (with NIH support)
for a decade or more are being terminated.
We hope that academic institutions,
patient organizations, and companies
together can find solutions to keeping
these important resources in service.
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Engineering a New Mouse Model for
Vitiligo
Prashiela Manga1 and Seth J. Orlow1
Although the precise mechanisms that trigger vitiligo remain elusive, autoimmune
responses mediate its progression. The development of therapies has been impeded
by a paucity of animal models, since mice lack interfollicular melanocytes, the primary
targets in vitiligo. In this issue, Harris et al. describe a mouse model in which
interfollicular melanocytes are retained by Kit ligand overexpression and an
immune response is initiated by transplanting melanocyte-targeting CD8þ T cells.
Journal of Investigative Dermatology (2012) 132, 1752–1755. doi:10.1038/jid.2012.140
Vitiligo
Melanocytes synthesize melanin, the pig-
ment that provides color to skin, hair,
and eyes, while protecting against sun-
induced damage. Vitiligo causes a selec-
tive, progressive loss of melanocytes,
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